Jamjoom Pharmaceuticals Factory Company (TADAWUL:4015)

Market Cap	11.07B
Revenue (ttm)	1.32B
Net Income (ttm)	356.52M
Shares Out	70.00M
EPS (ttm)	5.09
PE Ratio	31.08
Forward PE	26.95
Dividend	3.20 (2.00%)
Ex-Dividend Date	Mar 5, 2025

Volume	73,917
Average Volume	106,555
Open	157.20
Previous Close	159.80
Day's Range	155.00 - 159.80
52-Week Range	124.80 - 202.40
Beta	n/a
RSI	42.48
Earnings Date	Feb 25, 2025

About TADAWUL:4015

Jamjoom Pharmaceuticals Factory Company manufactures and markets pharmaceutical products in the Kingdom of Saudi Arabia and internationally. The company offers products human medicines, nutraceuticals, antibiotics, general analgesics, medicines for treatment of cough, allergy, asthma, heart diseases, blood pressure, diarrhea, vomiting, ulcer, and acidity, as well as various skin infections, cancer diseases, eye drops and ointments, and cosmeceuticals. Jamjoom Pharmaceuticals Factory Company was founded in 1994 and is based in Jeddah, the Kingdo...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1994
• Country: Saudi Arabia
• Stock Exchange: Saudi Stock Exchange
• Ticker Symbol: 4015

Financial Performance

In 2023, TADAWUL:4015's revenue was 1.10 billion, an increase of 20.09% compared to the previous year's 916.67 million. Earnings were 292.40 million, an increase of 70.68%.